Trial Outcomes & Findings for Low Cost QTc Meter for Long QT Syndrome Screening in Primary Care (NCT NCT04441892)

NCT ID: NCT04441892

Last Updated: 2023-07-25

Results Overview

Number of subjects to have a successful tracing recorded with the QTc Meter in Participants with or without Long QT Syndrome between the ages of 0 and 5

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

33 participants

Primary outcome timeframe

Baseline

Results posted on

2023-07-25

Participant Flow

Participant milestones

Participant milestones
Measure
QTc Meter
Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device QTc Meter: Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.
QTc Meter - Healthy Controls
Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device. QTc Meter: Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.
Overall Study
STARTED
28
5
Overall Study
COMPLETED
28
5
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Low Cost QTc Meter for Long QT Syndrome Screening in Primary Care

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
QTc Meter
n=28 Participants
Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device QTc Meter: Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.
QTc Meter - Healthy Controls
n=5 Participants
Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device. QTc Meter: Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.
Total
n=33 Participants
Total of all reporting groups
Age, Continuous
2.2 years
STANDARD_DEVIATION 1.5 • n=5 Participants
2.8 years
STANDARD_DEVIATION 1.6 • n=7 Participants
2.2 years
STANDARD_DEVIATION 1.5 • n=5 Participants
Sex: Female, Male
Female
15 Participants
n=5 Participants
1 Participants
n=7 Participants
16 Participants
n=5 Participants
Sex: Female, Male
Male
13 Participants
n=5 Participants
4 Participants
n=7 Participants
17 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=5 Participants
1 Participants
n=7 Participants
2 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
27 Participants
n=5 Participants
4 Participants
n=7 Participants
31 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
n=5 Participants
1 Participants
n=7 Participants
2 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
White
27 Participants
n=5 Participants
3 Participants
n=7 Participants
30 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
1 Participants
n=7 Participants
1 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
United States
28 participants
n=5 Participants
5 participants
n=7 Participants
33 participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline

Number of subjects to have a successful tracing recorded with the QTc Meter in Participants with or without Long QT Syndrome between the ages of 0 and 5

Outcome measures

Outcome measures
Measure
QTc Meter
n=28 Participants
Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device QTc Meter: Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.
QTc Meter - Healthy Controls
n=5 Participants
Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device. QTc Meter: Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.
Low Cost QTc Meter for Long QT Syndrome Screening
20 Participants
4 Participants

Adverse Events

QTc Meter

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

QTc Meter - Healthy Controls

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Michael J. Ackerman

Mayo Clinic

Phone: 507-284-8900

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place